Clinical Pearls for Treating Metastatic Colorectal Cancer

Opinion
Video

Marwan G. Fakih, MD, and Atif Hussein, MD, MMM, FACP, conclude their discussion with advice for clinicians treating patients with metastatic colorectal cancer.

This is a synopsis of an Insights series featuring Marwan G. Fakih, MD, of City of Hope, and Atif Hussein, MD, MMM, FACP, of Memorial Healthcare System.

Asked for final recommendations about the trifluridine/tipiracil and bevacizumab combination, Dr. Hussein emphasized the phase 3 SUNLIGHT trial data clearly demonstrate efficacy without needing complicated analysis. He would educate physicians on potential adverse effects like neutropenia, which likely caused the 12% discontinuation rate in the clinical trial setting. However, with appropriate growth factor support allowed in real-world practice, tolerance should improve. Likewise, properly advising the one week break in the 28-day treatment cycle facilitates intervening with growth factors.

Because oral therapies often encounter insurance obstacles, Dr. Hussein stressed the importance of enlisting pharmacists to facilitate approvals and affordability. Some oncologists may doubt rechallenging with bevacizumab in the third line so extensive education around the proven benefits is warranted. Avoiding underutilization will require highlighting the optimal administration schedule, proactively managing adverse effects, and securing financial assistance.

In closing, Dr. Fakih thanked Dr. Hussein for reviewing how the SUNLIGHT trial established trifluridine/tipiracil and bevacizumab as the clear standard of care in third-line metastatic colorectal cancer. While optimal adoption requires physician education on implementation strategies, the impressive survival data should provide strong motivation to learn proper administration, toxicity mitigation, and access support.

*Video synopsis is AI-generated and reviewed by Cancer Network editorial staff.

Recent Videos
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
Related Content